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Abstract: Attention deﬁ  cit hyperactivity disorder (ADHD) is a neurobehavioral developmental 
disorder found in 3% to 8% of children and adolescents. An important part of ADHD manage-
ment is psychopharmacology, which includes stimulants, norepinephrine reuptake inhibitors, 
alpha-2 agonists, and antidepressants. Medications with the best evidence-based support for 
ADHD management are the stimulants methylphenidate and amphetamine. A number of newer, 
long-acting stimulants are now available and a number of new medications are considered that 
are under current research.
Keywords: ADHD, methylphenidate, amphetamine, norepinephrine reuptake inhibitors, alpha-2 
agonists, antidepressants
Introduction
Attention deﬁ  cit hyperactivity disorder (ADHD) is a neurobehavioral developmental 
disorder with neurotransmitter dysfunction of the noradrenergic, dopaminergic, and 
serotonergic systems. It is present in 3% to 8% of children and adolescents and has 
characteristics of inattentiveness with or without impulsivity.1–6 A thorough history 
and physical examination is necessary to make this diagnosis.7–9 Management includes 
providing appropriate psychological therapy, insuring proper school placement, and, 
if necessary, judicious use of anti-ADHD medications.1,2 This report summarizes 
current concepts in ADHD psychopharmacology speciﬁ  cally the use of stimulants, 
alpha-2 agonists, and anti-depressants. Other medications under research are also 
considered.
Stimulant medications
Research in the 20th century revealed that stimulant medications were useful in improv-
ing attentional dysfunction in children and adolescents.10 Indeed, hundreds of studies 
conducted over the past 60+ years have consistently demonstrated the effectiveness 
of stimulant medications in improving attention dysfunction associated with ADHD 
in children, adolescents, and adults.11–20 Research notes improvement in concentra-
tion ability in 75% to 95% of those with ADHD on stimulants. The success of this 
pharmacologic approach has resulted in increasing use of stimulants for ADHD with 
6% of pediatric patients 5 to 15 years of age being placed on stimulant medication in 
the United States.21,22
Methylphenidate
General considerations
MPH (methylphenidate) has been available in the United States since the late 1950s 
and has become the most common stimulant medication used to treat ADHD because 
of its beneﬁ  cial effect on problems with concentration. Its pharmacologic effects are 
based on selective binding of the presynaptic dopamine transporter in the central Neuropsychiatric Disease and Treatment 2009:5 172
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nervous system (particularly the striatal and prefrontal areas) 
that result in a rise in extracellular dopamine in the central 
nervous system (CNS).14,20,23 Table 1 lists medications used 
to treat ADHD that have evidence-based research and notes 
their dosages and common side effects.
MPH is a schedule II medication produced in short-acting 
and long-acting oral formulations (Table 2). Short-acting 
MPH is marketed as Ritalin® (and other brand names) or its 
generic version and after oral ingestion, pharmacologic action 
is noted in 30 to 45 minutes that peaks in 1 to 2 hours, and 
fades away over 3 to 5 hours. This short acting formulation 
requires one to three doses a day as desired by the child or 
adolescent to improve attentional dysfunction. One should 
not exceed a single dose over 20 mg or a daily dosage over 
60 to 80 mg while the patient is titrated to the dosage regimen 
best suited for him or her.
MPH preparations
After the development of MPH as a short-acting stimulant, 
a longer-acting product became available, Ritalin SR®. 
It comes as a 20 mg sustained released tablet that results in 
a release of about 7 mg of short-acting MPH over several 
hours. Since Ritalin SR® only comes in a 20 mg tablet and 
unpredictable gastrointestinal absorption is noted in half 
of its users, pharmaceutical companies launched a search 
for additional MPH products, mostly those with a longer-
acting effect. Table 2 lists these newer longer-acting MPH 
products while Table 3 notes reasons for failure of beneﬁ  t 
from psychostimulant medications.1,6,11–19 Though there 
has been intense advertising by the manufacturers of these 
newer products that one is better than another or that long-
acting formulations are “better” than short-acting, there is 
no neutral scientiﬁ  c evidence to sustain such statements. 
A trial and error method is necessary to determine what 
speciﬁ  c product or products are best for a speciﬁ  c child or 
adolescent with ADHD. Some of these newer products are 
discussed below.
An MPH patch (Daytrana®) was released in June 2006 
and allows effect for up to 12 hours; it is applied in the 
morning and removed in the afternoon or evening, providing 
Table 1 Medications with research support for use in attention disorders
Medication Daily dose (mg/kg) schedule Common untoward effects
Stimulants
  Methylphenidate 0.3–2.0 (10–80 mg/day) in 2–4 divided 
doses 
Insomnia, decreased appetite, abdominal pain, 
headache, depression, loss of weight, rebound 
symptoms, decreased velocity versus growth delay. 
See text
  Magnesium pemoline 0.5–3.0 (37.5–131.25 mg/day)
In 1–2 divided doses
Same as methylphenidate + possible liver toxicity 
(new FDA Black Box warning)
  Dextroamphetamine 0.1–1.5 (5–80 mg/day) in 2–4 divided 
doses
Same as methylphenidate but more depression
Antidepressants
 Tricyclic  antidepressants
  imipramine
  desipramine
  nortriptyline
1–5
1–5
0.5–3
Anticholinergic effects, others. See text
  Bupropion 3–6 (50–300 mg/day) in 2–3 divided 
doses 
Insomnia, irritability, drug-induced seizures (with 
doses 6 mg/kg)
Contraindicated in bulimic patients
Alpha-2 agonists
 Clonidine 3–10  μg/kg (0.05–0.4 mg/day) in
2–4 divided doses
Sedation (very frequent), depression, dry mouth, 
rebound hypertension, hypotension (rare), 
confusion (with high doses), Localized irritation 
with transdermal preparation
 Guanfacine 15  –43 μg/kg (0.5–4.0 mg/day) in 1–2 
divided doses
Same as clonidine but much less sedation, less 
hypotension
Norepinephrine reuptake inhibitors
  Atomoxetine 0.5–1.4 mg/kg/day in 1–2 divided doses Decreased appetite, dyspepsia, dizziness, fatigue, 
sedation, nausea emesis, mood swings, growth delay
Adapted with permission from Greydanus DE, Sloane MA, Rappley MD. Psychopharmacology of ADHD in adolescents.   Adolesc Med. 2002;13:599–624.11 Copyright © 2002 
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10 to 30 mg of MPH depending on the patch size used.1,14–16 
Approximately half the patients develop some type of skin 
reaction. Ritalin LA® is an MPH capsule manufactured as 
a 20 mg, 30 mg, and 40 mg capsule with similar amounts 
of IR (immediate release) and SR (sustained release) beads 
that result in release of MPH up to 8 hours as if two IR 
formulations were taken 4 hours apart.1,14 The recommended 
practice is to begin with a daily 20 mg capsule and slowly 
increase if needed to the 40 mg capsule. Metadate CDTM is 
produced as a 20 mg MPH capsule with coated beads that 
Table 2 Methylphenidate preparations
Brand name 
(in USA)
Dosage form Dosing regimen Duration of 
effect in hours Start Titrate weekly Maximum per day
Active ingredient: d, l, methylphenidate
Ritalin; generic 
form available
Scored tablets: 5, 10, 20 mg 5 mg 2–3 times/day; 
1 dose before break-
fast, 1 before lunch
5–10 mg; Give a third 
dose in the afternoon if 
needed
Not to exceed 
20 mg/dose; 60 mg/day
3–4
Ritalin SR Sustained release tablets: 
20 mg
20 mg before breakfast 20 mg; Give a second 
dose in afternoon if 
needed; for desired 
dose and duration, 
short acting form may 
be used
60 mg 6–8
Ritalin LA Long-acting capsules; 10, 20, 
30, 40 mg; can be sprinkled
10 mg before breakfast 5–10 mg; use short 
acting form (Ritalin) to 
titrate if needed
60 mg 4–8
Methylin Scored tablets: 5,10,
20 mg; chewable tablets: 
2.5, 5, 10 mg; oral solution: 
5 mg/mL, 10 mg/10 mL
5 mg 2–3 times/day; 
1 dose before 
breakfast, 1 before 
lunch
5–10 mg; Give a third 
dose in the afternoon if 
needed
Not to exceed 
20 mg/dose; 60 mg/day
3–4
Methylin ER Extended release tablets: 
10, 20 mg
10 mg before breakfast 10 mg; give a second 
dose in afternoon if 
needed
60 mg 4–8
Metadate ER Extended release tablets: 
10, 20 mg
10 mg before breakfast 10 mg; Give a second 
dose in afternoon if 
needed
60 mg 4–8
Metadate CD Extended release capsules: 
10, 20, 30 mg. Can be 
sprinkled
20 mg before breakfast 20 mg; Give a second 
dose in the afternoon if 
needed
60 mg 4–8
Concerta Capsules: 18, 27, 36, 54 mg; 
do not split or chew or 
crush
18 mg before breakfast 18 mg 72 mg 8–12
Daytrana Transdermal patch: 10, 15, 
20, 30 mg
10 mg patch applied 
2 hour before desired 
effect; remove 9 hours 
later
10 mg 30 mg 12
Active ingredient: d, methylphenidate
Focalin Scored tablets: 2.5, 5, 10 mg 2.5 mg 1–2 times a day 2.5 mg; Give a third 
dose in afternoon if 
needed.
30 mg 4–6
Focalin XR Extended release capsules: 
5, 10 mg; can be sprinkled
5 mg before breakfast 5 mg; Give a second 
dose in afternoon if 
needed; for desired 
dose and duration short 
acting form (Focalin) 
may be used
30 mg 8–12
Reproduced from Greydanus DE, Calles JL, Patel DR. Pediatric and Adolescent Psychopharmacology. Cambridge, England: Cambridge University Press; 2008. p. 83–84.14Neuropsychiatric Disease and Treatment 2009:5 174
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allows immediate release of 30% of the MPH and sustained 
release of the remaining MPH over 6 to 10 hours. Begin 
with the 20 mg capsule and carefully titrate to 60 mg a day 
if necessary.
Focalin® (dexmethylphenidate hydrochloride) is the 
d-threo-enantiomer of racemic MPH that is produced as 
2.5 mg, 5 mg, and 10 mg tablets lasting 4 to 6 hours; it is 
developed in formulations that are half the dose of regular 
MPH and is based on the concept that the d-threo-enantiomer 
is more active pharmacologically than the l-threo-enantiomer. 
Methylin® is another short-acting MPH product produced as 
5, 10, and 20 mg tablets while Methylin ER is an extended 
MPH product made in 10 and 20 mg tablets for an effect 
lasting up to 8 hours.
Concerta® is a sustained release MPH product that uses 
the OROS mechanism or osmotic release process in which 
there is a tri-layer core covered by a semi-permeable mem-
brane with a laser-drilled hole on one end.1,14 There is both 
immediate release of MPH (22%) from the overcoat and 
then a gradual release of MPH lasting up to 10 to 16 hours. 
Concerta® comes as 18 mg, 36 mg, and 54 mg capsules taken 
once a day. One advantage of this product is that it is very 
difﬁ  cult if not impossible to alter it for consumption as an 
illicit drug to develop euphoric effects.
Amphetamines
General considerations
Amphetamines have been known in medical and biochemi-
cal circles since the late 1800s and the ﬁ  rst observation of 
their beneﬁ  cial impact on attentional dysfunction in children 
dates back to Bradley’s 1937 publication on Benzedrine.35 
Research over the past several decades has noted that 
dextroamphetamine (Dexedrine®; Dextrostat®) is another 
psychostimulant that improves concentration in children, 
adolescents, and adults. It can be used in place of or as 
an alternative to MPH for pharmacologic management of 
ADHD. Effects of this medication last for 3 to 6 hours with 
an average of 5 hours. Pharmacologic action is due to CNS 
dopamine rise because of dopamine transporter binding.14,20 
Side effects are similar to those of MPH products including 
the well-known addiction potential.
Amphetamine products
Table 7 lists available amphetamine formulations. Dextro-
amphetamine is available in 5 mg and 10 mg scored tablets 
and is prescribed 1 to 3 times a day as needed; generic for-
mulations are also produced. As with MPH, careful titration 
is recommended to ﬁ  nd the best dosage plan for each patient 
and 40 to 50 mg a day should not be exceeded. A formulation 
lasting 8 to 10 hours is also noted, Dexedrine® Spansule®, 
and it is available in 5 mg, 10 mg, and 15 mg capsules. 
Sometimes these short-acting and long-acting formulations 
can be combined as well for optimal improvement of ADHD 
symptoms.
Another short-acting amphetamine version is meth-
amphetamine (Desoxyn®) sold in 5 mg tables that provide 
effects for 4 hours. However, it has the highest addiction 
record of all the prescription amphetamines and is difﬁ  cult 
to ﬁ  nd in the United States. A newer long-acting formula-
tion of dextroamphetamine, Vyvanse® (lisdexamfetamine), 
has been available since 2007 and provides beneﬁ  t for up to 
12 hours in a constant rate release and with reduced risks of 
addiction and overdose.1,36,37
Adderall®, another long-acting amphetamine, is a mixed-
salts amphetamine product with 25% of the l-isomer and 
75% of the d-isomer that lasts 8 to 12 hours; it is produced 
in scored tablets of various dosage strengths: 5 mg, 7.5 mg, 
10 mg, 12.5 mg, 15 mg, 20 mg, and 30 mg. A longer acting 
version is Adderall XR® that produces a pulsed amphetamine 
salts release with stimulant effects up to 12 hours; it is pro-
duced as 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg 
capsules.
Pemoline
Pemoline (magnesium pemoline) is a psychostimulant of 
historical signiﬁ  cance as it was available as a long-acting 
stimulant for several decades.1,14 This medication was taken 
as a once a day dose and is no longer produced in the United 
States because of a rare, but well-known development of 
irreversible liver failure. Informed, written consent for its 
prescription that overtly acknowledges the possibility of liver 
failure and death is necessary if it is prescribed.
Table 3 Reasons for failure of beneﬁ  t from stimulant medication
1. ADHD is not the actual diagnosis
2.  Concomitant disorders override any observable stimulant beneﬁ  t
3.  Failure to use the proper dose (too high or low)
4.  Refusal of child, adolescent, and/or parent to accept medications
5. ADHD type does not respond to stimulants or any medications
6.   Side effects of MPH and/or amphetamines are not tolerated by the 
patient
7.  Failure to start with a low dose and titrate slowly
8.   Use of the medication for other than amelioration of attentional 
dysfunction
   (ie, use of stimulants to alter negative behavior as seen with conduct 
disorders)Neuropsychiatric Disease and Treatment 2009:5 175
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Stimulant side effects
Side effects of stimulant medication (MPH or amphetamines) 
are noted in Table 4 and these can be found in both short-acting 
and long-acting (sustained release) forms.6,11–14,17–19 Table 5 
lists contraindications to stimulant use, whether MPH or 
amphetamine products. Avoidance or improvement in some of 
these adverse effects may occur with careful titration of these 
psychostimulants, beginning with a low dose and gradual 
increase to ﬁ  nd the best dosage regimen for each patient.
As many as 75% of children or adolescents with Tourette’s 
syndrome have concomitant ADHD and having tics is a relative, 
not absolute contraindication to use of psychostimulants.24–26 If 
the patient feels that the MPH or amphetamine formulation is 
improving the attentional dysfunction while inducing or worsen-
ing tics, adding anti-tic medications such as risperidone, halo-
peridol, or pimozide may be of beneﬁ  t. Some clinicians prefer 
to avoid stimulants in this situation and use anti-ADHD medica-
tions that do not worsen tics, such as α2 agonists (as clonidine or 
guanfacine), atomoxetine, or tricyclic antidepressants.
Sudden death has been reported on rare occasions in 
pediatric and adult patients taking MPH or amphetamine 
products, and atomoxetine.1,14,27,28 Though these medications 
are not known to be a direct cause of sudden death, they 
should be avoided in patients who have overt or symptom-
atic cardiovascular disease or uncontrolled hypertension. 
The American Heart Association has recommended that all 
children placed on stimulant medications for ADHD should 
receive a screening EKG; however, the American Academy 
of Pediatrics has concluded that this is neither necessary nor 
recommended.27,28 Recommendations for cardiovascular 
screening and stimulant use appear in Table 6.
Psychostimulants may induce mania in one with latent 
bipolar disorder or psychosis in one with latent schizophrenia. 
Interaction between MPH products and some anticonvulsants, 
including phenobarbital, phenytoin, and ethosuximide may 
occur. Most studies conclude that use of psychostimulants 
does not induce substance abuse disorder, though stimulants 
can be abused for euphoric effects.29–32 Thus, only those with 
clear evidence of ADHD should be prescribed psychostimu-
lants and careful observation should occur to seek to prevent 
the medication being diverted to others and/or used by the 
patient for purposes of getting high or selling these drugs. 
Youth may also use other drugs with stimulant qualities, 
such as caffeine, nicotine, or cocaine, to self-medicate their 
attention dysfunction.33,34 There is potential for addiction and 
withdrawal symptoms with all stimulant medications.
Tolerance occurs in some children or adolescents taking 
high stimulant doses and this phenomenon may improve 
with use of a different stimulant or lowering the dose of 
the same medication. Another phenomenon that has been 
seen in some on psychostimulant medication is rebound, in 
which the ADHD symptoms worsen when the medication 
is reduced or blood levels drop after the ingestion of the last 
dose.1,14 Changing the current combination of short-acting 
and/or long-acting stimulant may ameliorate rebound. 
Rebound noted in the early evening is difﬁ  cult to correct 
and sleep disturbances may result. Sleep dysfunction occurs 
in a number of those taking stimulants, especially the long-
acting formulations. Stimulant-induced sleep disturbances 
Table 4 Potential side effects of methylphenidate
 1. Abdominal  paina
 2. Anorexiaa
 3. Dizziness
 4. Headachea
 5. Insomniaa
 6. Jitterinessa
  7.  Insomnia (delayed onset of sleep)a
 8. Social  withdrawala
  9. Weight loss (due to decreased appetite)a
10. Appearance of being “dazed or drugged”; perseveration and withdrawal
11. Appearance of psychosis or psychotic manifestations
12.  Change in personality
13. Constipation
14. Dry  mouth
15. Increased  hyperactivity
16.  Increase in blood pressure, pulse, and palpitations
17. Moodiness  (irritability)
18. Nausea
19. Rebound  phenomenon
20. Skin  rash  (rare)
21. Tolerance
22. “Unmasking” of Tourette’s syndrome
aCommonly seen side effect.
Table 5 Contraindications to stimulant use
1.  Concomitant prescription with MOAs (monoamine oxidase inhibitors)
2. Glaucoma
3. Hyperthyroidism
4. Medication  sensitivity
5.  Overt cardiovascular disease
6. Psychosis
7.  Substance abuse disorders
8. Uncontrolled  hypertensionNeuropsychiatric Disease and Treatment 2009:5 176
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may improve by avoidance of sustained release stimulants, 
avoidance of all stimulant formulations in the afternoon or 
evening, and/or the addition of various sedative medications 
before bedtime, such as trazodone (25–50 mg), melatonin 
(3–6 mg), or mirtazepine (Remeron®) (7.5–15 mg).
Norepinephrine reuptake inhibitors
Atomoxetine
Atomoxetine, along with methylphenidates and amphet-
amines, are the only FDA-approved medications for ADHD. 
Atomoxetine is a norepinephrine reuptake inhibitor that blocks 
the presynaptic norepinephrine transporter in the prefrontal 
cortex without primary effects on dopamine levels.38–42 It 
has been recommended for those with ADHD where psy-
chostimulants are not desired, tolerated, or effective.6,41 It 
is a non-stimulant anti-ADHD medication available since 
2003 and produced in a variety of capsule strengths: 10 mg, 
18 mg, 25 mg, 40 mg, and 60 mg. The recommended start-
ing dose for the child 70 kg or less is 0.5 mg/kg/day that is 
increased at least every 3 days to 1.2 mg/kg/day given as a 
single dose or in 2 divided doses. The maximum dose should 
not exceed 1.4 mg/kg/day or 100 mg per day. The duration 
of effect is 18 to 24 hours.
Side effects of atomoxetine are listed in Table 8.38–42 There 
are drug-to-drug interactions that involve selective serotonin 
reuptake inhibitors and others metabolized by cytochrome 
P450 2D6; it has a low afﬁ  nity for various receptors, such 
as serotonergic, cholinergic, histaminic, alpha1-adrenergic, 
and alpha2-adrenergic. Cardiovascular complications, tics, 
drug diversion, and drug addiction are not associated with 
atomoxetine. The US FDA issued a black box warning for 
use of atomoxetine because of an increase in suicidality in 
patients taking this medication.41 Children and adolescents 
who are placed on this medication should be observed for 
the next few months for agitation, suicidality, or irritability 
that occur with drug initiation or dosage change. There is an 
increase risk for mydriasis and it must be avoided in those 
with narrow angle glaucoma. Baseline liver function tests 
and periodic monitoring are necessary because of anecdotal 
reports of severe liver injury. Studies are currently evaluat-
ing the potential added beneﬁ  t of atomoxetine taken with 
stimulants.
Alpha-2 agonists
General considerations
Alpha2-adrenergic agonists (such as clonidine or guanfacine) 
have been noted to be beneﬁ  cial for some patients with 
ADHD because of their sedative effects helping to combat 
the sleep dysfunctional aspects of MPH.1,6,11,12,18 Those who 
have only attentional dysfunction may develop impaired 
neuropsychological effects if placed on clonidine or guan-
facine.
Clonidine
Clonidine is available as a pill and patch in three dosages: 
0.1 mg, 0.2. mg, and 0.3 mg; the pill formulation is pre-
scribed 2 to 4 times a day or at bedtime starting with the 
lowest formulation.
Table 6 Cardiovascular screening
Personal history
  Exertional chest pain
  Shortness of breath
 Presyncope
 Syncope
 Dizziness
 Palpitations
 Fatigue
  Recent febrile illness
  Congenital heart disease
 Heart  murmur
 Hypertension
  Lipid disorder or abnormalities
Past history
 Kawasaki’s  disease
 Rheumatic  fever
Family history
 Marfan  syndrome
 Cardiomyopathy
  Long QT syndrome
  Premature cardiac death (before age 50)
 Hypertension
 Lipid  disorders
Cardiovascular exam
   Heart rate; blood pressure; delayed femoral arterial pulses 
(coarctation of aorta)
   Systolic ejection murmur that intensiﬁ  es with standing or Valsalva 
maneuver and diminishes with squatting (hypertrophic cardiomyopathy)
   Decrescendo diastolic murmur of aortic valve insufﬁ  ciency (may be 
present in Marfan syndrome)
   Holosystolic murmur of mitral valve insufﬁ  ciency (may be present in 
Marfan syndrome)
  Systolic ejection murmur or midsystolic clicks (mitral valve prolapse)
Reproduced from Greydanus DE, Calles JL, Patel DR. Pediatric and Adolescent Psycho-
pharmacology. Cambridge, England: Cambridge University Press; 2008. p. 91.14Neuropsychiatric Disease and Treatment 2009:5 177
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The dosage range for clonidine is 0.05 to 0.4 mg and it is 
important to slowly titrate the medication to reduce potential 
side effects, as listed in Table 9. Slow reduction of clonidine 
is recommended when stopping this drug to reduce the pos-
sibility of rebound hypertension. The patch formulation is 
effective for 3 to 7 days and local dermatitis may occur in a 
few using the patch. Use of the clonidine patch may prevent 
or ameliorate sedative as well as blood pressure effects seen 
with the oral formulation. Baseline studies before starting this 
medication include a blood pressure, pulse, blood glucose, 
and an electrocardiogram (EKG); such testing may be 
repeated periodically, especially if changing doses. An EKG 
can be done every 6 months if the child or adolescent remains 
on clonidine. There are reports of a few cases of sudden 
deaths in pediatric patients taking MPH and clonidine.
Guanfacine
This is an alpha2A-adrenergic agonist that may lead to less 
sedation and hypotension compared with clonidine.11,12,18 In 
addition, there may be increased prevalence of headaches and 
agitation with use of guanfacine. This medication is avail-
able as 1 mg and 2 mg tablets while the daily dosage range 
is 0.5 mg to 4 mg. Guanfacine XR is an extended release 
form that is being considered for ADHD management in 
pediatric patients.43,44
Antidepressants
Tricyclic antidepressants (TCAs)
An alternative to psychostimulants for several decades has 
been TCAs as listed in Table 101,6,11,12,14 while Table 11 
lists potential side effects of TCAs. Children or adolescents 
placed on TCAs should be carefully monitored with vital 
signs, complete blood count, serum TCA levels, and an EKG. 
Protocols for management have been published.45–47 Sudden 
deaths have been rarely reported in pediatric patients taking 
both TCAs and MPH.45,46
Table 7 Amphetamine preparations
Brand name 
(in USA)
Dosage form Dosing regimen Duration of 
effect (hours) Start Titrate 
weekly
Maximum 
per day
Active ingredient: Dextroamphetamine
Dexedrine (generic 
form available)
Tablets: 5 mg 5 mg 1–2 times/day 5 mg 40 mg 4–6
Dextrostat Scored tablets: 5, 10 mg 2.5–5 mg 1–2 times/day 5 mg 40 mg 4–6
Generic form Extended release capsules: 
5, 10, 20 mg
5 mg 1–2 times/day 5 mg 40 mg 4–6
Dexedrine 
Spansule
Spansules: 5, 10, 15 mg; can 
be sprinkled
5 mg before breakfast 5 mg 45 mg 6–10
Active ingredient: Mixed salts of amphetamine (dextroamphetamine plus levoamphetamine)
Adderall (generic 
form available)
Tablets: 5, 7.5, 10, 12.5, 15, 
20, 30 mg
5–10 mg 1–2 times/day; 
1 dose before breakfast, 
second before lunch
5–10 mg 40 mg 4–6
Adderall XR Extended release capsules: 
5, 10, 15, 20, 25, 30 mg; can 
be sprinkled
5–10 mg before 
breakfast
5–10 mg 30 mg 8–12
Reproduced from Greydanus DE, Calles JL, Patel DR. Pediatric and Adolescent Psychopharmacology. Cambridge, England: Cambridge University Press; 2008. p. 85.
Table 8 Potential atomoxetine side effects
Anorexia
Constipation
Dizziness
Dry mouth
Dyspepsia
Emesis
Fatigue
Heightened pulse and blood pressure
Mood swings (FDA Black Box warning on increased suicidal thinking in 
children and adolescents)
Nausea up to several weeks
Sedation or insomnia
Sexual dysfunction
Voiding difﬁ  cultyNeuropsychiatric Disease and Treatment 2009:5 178
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Bupropion
Another antidepressant that has been used to manage 
attentional dysfunction of ADHD is bupropion (Table 1), 
a medication also used to treat tobacco addiction as the 
formulation ZybanTM in addition to depression and ADHD 
as Wellbutrin®.32,48,49 It is available as 75 and 100 mg tablets 
and the daily dosage range is 50 to 300 mg for depression 
and ADHD – not over 6 mg/kg per day. Other bupropion 
preparations include two sustained release formulations – 
Wellbutrin SR® (100 mg and 150 mg) given twice a day and 
Wellbutrin XL® given once a day.
Table 12 lists side effects of bupropion and includes 
seizures with an incidence of 0.1% if the dosage is less than 
300 mg per day and 0.4% if over 300 mg a day.14 Head 
trauma, epilepsy, and bulimia nervosa are contraindications 
for bupropion. Also, the risks for seizure activity is lessened 
by slow drug titration, avoidance of taking it less than 8 hours 
apart, avoidance of prescription for high amounts of the 
regular formulation, and prescription of the sustained release 
formulations. One beneﬁ  t of bupropion is that interactions 
with other medications are of minimal signiﬁ  cance, except 
for the interaction with MAOIs. Bupropion is metabolized 
by the cytochrome P450 system and has the potential to 
interact with other agents that affect the 2B6 isoenzyme (ie, 
desipramine, paroxetine, sertraline, others). It does carry an 
FDA black box warning about suicidality though it does not 
lead to cardiac conduction delays as noted with TCAs.
Venlafaxine
Venlafaxine is an atypical antidepressant that some clini-
cians use for ADHD and is considered a second or third-line 
agent.1,14,50 It selectively inhibits norepinephrine and sero-
tonin reuptake and weakly inhibits dopamine uptake. It is 
available in 25, 50, 75, and 100 mg tablets for oral administra-
tion. The dosage is 1 to 3 mg/kg/day or 37.5 to 225 mg/day. 
As with the use of other antidepressants, it is important to 
observe children and adolescents on venlafaxine for the risk 
of suicidality. Sustained hypertension, which is dose-related, 
may occur in patients receiving this antidepressant. Since 
mydriasis may occur, venlafaxine can be harmful to a patient 
with increased intraocular pressure or one at risk for acute 
narrow-angle glaucoma. Drug interactions with MAOIs are 
well-known. Venlafaxine is metabolized by numerous isoen-
zymes of the cytochrome P450 system and has the potential 
for multiple drug interactions. Caution should be exercised 
when adding medications to venlafaxine. It is contraindicated 
in individuals with heart disease.
Modaﬁ  nil
A newer antidepressant is modaﬁ  nil, which acts in many 
ways like the sympathomimetic agents; however, it is 
unique in that it does not bind to catecholamine receptors 
nor increase adrenergic activity.51–55 Its exact mechanism of 
promoting alertness and wakefulness is unknown, though it 
has pharmacologic effects in the thalamus, hippocampus, and 
central nucleus of the amygdala. Current FDA approved uses 
include narcolepsy and obstructive sleep apnea/hypopnea 
syndrome (OSAHS).14 It has not been FDA-approved for 
children and adolescents with ADHD. Modaﬁ  nil is available 
for oral administration as 100 mg and 200 mg tablets. Typical 
dosing in children with ADHD is 50 to 100 mg daily.
Some common side effects include headache, gastroin-
testinal disturbances, nervousness, dizziness, anxiety (dose-
related), and insomnia. As with other stimulants, modaﬁ  nil 
can be harmful to patients with a history of cardiovascular 
Table 9 Side effects of clonidine
Sedation (50%)
Attentional dysfunction
Dry mouth
Headache
Depression
Dizziness
Dysphoria
Effects that are not consistent
Fatigue
Irritability
Itchy eyes
Neuroleptic anticholinergic side effects potentiation
Patch-induced dermatitis
Postural hypotension
Rebound phenomenon
Reduced glucose tolerance
Tolerance
Weight gain
Withdrawal effects due to sudden cessation leading to severe hyperten-
sion and rebound tachycardia
Worsening of pre-existing cardiac arrhythmias
Table 10 Tricyclic antidepressants
Tricyclic antidepressants Dosage range
Imipramine (Tofranil®, others) 50–200 mg/day
Desipramine (Norpramin®, Desipramine®) 50–200 mg/day
Amitriptyline (Elavil®) 50–200 mg/day
Nortriptyline (Pamelor®) 20–100 mg/dayNeuropsychiatric Disease and Treatment 2009:5 179
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disease or Tourette’s syndrome and caution should be used 
in patients with a history of psychosis. Modaﬁ  nil has the 
propensity for drug interactions since it is metabolized by 
the cytochrome P450 system and can act as an inducer or 
inhibitor of the cytochrome P450 system.
Medications for the future
Future research will divide ADHD into various subtypes 
depending on a more precise knowledge of what parts of 
the CNS are involved as classiﬁ  cation of ADHD becomes 
more sophisticated.1 This will allow the development of 
additional medications targeted at speciﬁ  c CNS pathways.56 
Long-acting formulations of drugs already used for ADHD 
management will continue to be developed and utilized.57 
However, careful titration is important for each patient, 
since some do best with short-acting stimulants, others with 
long-acting stimulants, and still others with a combination 
of both.14,58
AMPA (ampakines) receptor modulators (such as CX-717) 
are used as memory enhancer drugs and may be utilized in 
the future as beneﬁ  cial anti-ADHD drugs.1,59,60 Nicotinic 
acetylcholine receptor antagonists are also under current 
research as medication to enhance attentional dysfunction in 
ADHD patients.60–62 Dopamine agonists (such as ropinirole) 
are used to treat restless legs syndrome and have been shown 
to improve attention span.63–65 Atypical antipsychotics 
(such as aripiprazole and risperidone) are being researched 
as anti-ADHD drugs especially if there are co-morbidities 
present as conduct disorder or bipolar disorder.66,67 Studies are 
also evaluating the potential role of selective noradrenaline 
reuptake inhibitors (such as reboxetine mesylate) for ADHD 
management.68 Finally, GABA B receptor antagonists (such as 
SGS-742) are being studied as potential anti-ADHD drugs.60
Summary
US FDA medications approved to treat ADHD in children 
and adolescents include methylphenidate and amphetamine 
products in addition to atomoxetine. Other medications used 
for ADHD management include alpha-2 agonists, antidepres-
sants (tricyclic antidepressants, bupoprion, and venlafaxine), 
and modaﬁ  nil.1,14 Despite intense pharmacologic advertise-
ments, there are no short-acting or long-acting psychostimu-
lants that are proven to be superior to the others.1,14,36,41,69–72 
All these drugs have adverse effects and a careful titration 
of these medications with the individual patient is necessary 
for optimal drug efﬁ  cacy and patient safety.73–75 The future 
looks promising for the development of newer anti-ADHD 
drugs in the 21st century.
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